Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × Crizotinib × Clear all

Phase

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Relapsed Pediatric Solid Tumor 1 Recurrence 1 Lung Neoplasms 1 Lung Adenocarcinoma Metastatic 1 Granuloma, Plasma Cell 1 Gallbladder Neoplasms 1 ALK-positive NSCLC 1

Interventions

Cyclophosphamide 16 fludarabine 12 Cisplatin 11 Rituximab 9 Dexamethasone 9 Gemcitabine 8 Cytarabine 7 fludarabine phosphate 6 Paclitaxel 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Lenalidomide 6 Decitabine 6 Radiotherapy 5 Etoposide 5 Carboplatin 5 Bendamustine Hydrochloride 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Injections 4 Bortezomib 4 Antilymphocyte Serum 4 tislelizumab 3 pomalidomide 3 Vinorelbine 3 Vinblastine 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡